Massachusetts Financial Services CO Prothena Corp Public LTD CO Transaction History

Massachusetts Financial Services CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$22.73 - $39.98 $308,127 - $541,968	-13,556 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$30.27 - $49.22 $856,701 - $1.39 Million	-28,302 Reduced 67.61%	13,556 $496,000
Q4 2021 Feb 10, 2022	SELL	$42.11 - $73.26 $35,709 - $62,124	-848 Reduced 1.99%	41,858 $2.07 Million
Q3 2021 Nov 10, 2021	SELL	$48.2 - $78.89 $27,088 - $44,336	-562 Reduced 1.3%	42,706 $3.04 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $650,435 - $1.73 Million	-30,071 Reduced 41.0%	43,268 $2.22 Million

Q1 2021 May 13, 2021	SELL	$11.0 - $28.24 $387,805 - $995,601	-35,255 Reduced 32.46%	73,339 $1.84 Million
Q4 2020 Feb 12, 2021	BUY	$10.12 - $13.94 $216,294 - $297,939	21,373 Added 24.5%	108,594 $1.3 Million
Q3 2020 Nov 12, 2020	BUY	$9.93 - $13.47 $866,104 - $1.17 Million	87,221 New	87,221 $871,000

186

45.4M

119K

144K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $968M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.